BioAtla, Inc. (BCAB) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $3.43 (-5.25%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| May 23, 2024 | Reni Benjamin | JMP Securities | $250.00 | +7188.4% |
Top Analysts Covering BCAB
BCAB vs Sector & Market
| Metric | BCAB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | — | 2.24 | 2.40 |
| Analyst Count | — | 8 | 19 |
| Target Upside | +6359.9% | +11467.3% | +17.1% |
| P/E Ratio | -0.08 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $20M | $20M | $20M | 2 |
| 2027-12-31 | $4M | $4M | $4M | 1 |
| 2028-12-31 | $55M | $55M | $55M | 1 |
| 2029-12-31 | $239M | $239M | $239M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-46.00 | $-46.00 | $-46.00 | 1 |
| 2027-12-31 | $-58.50 | $-58.50 | $-58.50 | 1 |
| 2028-12-31 | $-45.00 | $-45.00 | $-45.00 | 1 |
| 2029-12-31 | $-48.00 | $-48.00 | $-48.00 | 1 |
Frequently Asked Questions
What is the analyst consensus for BCAB?
The consensus among 0 analysts covering BioAtla, Inc. (BCAB) is — with an average price target of $250.00.
What is the highest price target for BCAB?
The highest price target for BCAB is $250.00, set by Reni Benjamin at JMP Securities on 2024-05-23.
What is the lowest price target for BCAB?
The lowest price target for BCAB is $250.00, set by Reni Benjamin at JMP Securities on 2024-05-23.
How many analysts cover BCAB?
0 analysts have issued ratings for BioAtla, Inc. in the past 12 months.
Is BCAB a buy or sell right now?
Based on 0 analyst ratings, BCAB has a consensus rating of — with a +6359.9% upside to the consensus target of $250.00.
What are the earnings estimates for BCAB?
Analysts estimate BCAB will report EPS of $-46.00 for the period ending 2026-12-31, with revenue estimated at $20M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.